BLUEMATRIX
24.7.2024 10:01:29 CEST | Business Wire | Press release
BlueMatrix, the world’s largest publisher of investment research, has announced that, since the start of 2024 and a strategic growth investment by leading software investment firm’s Thoma Bravo, new revenue has grown an impressive 74% on the same period last year. BlueMatrix is doubling down on its investment in its clients through a growth strategy that includes strengthening its leadership team with two major C-suite appointments. Its new Chief Financial Officer and Chief Revenue Officer have over 40 years of combined experience in scaling software companies within the financial services landscape.
Joining BlueMatrix’s leadership team, overseen by Chief Executive Officer and President Patricia Horotan and alongside Chief Operating Officer Mirko Consolascio, is Ben McFadden, appointed as Chief Financial Officer. He brings more than 15 years of enterprise software strategic finance expertise. He was previously Head of Finance at Nintex, a leader in global automation software, and Revalize, a quote-to-cash provider for manufacturing. His prior experience includes five years as a sell-side equity research analyst at Keybanc Capital Markets focused on infrastructure software.
Ben McFadden commented: “I witnessed BlueMatrix’s trajectory firsthand seven years ago as a sell-side equity analyst and now I get to be a part of this exceptional team. My focus is on maintaining our impressive 97% customer retention, enabled by our international expertise, industry-leading products, and outstanding service. With Thoma Bravo's strategic investment too, I believe the future for BlueMatrix is very bright indeed.”
Also joining BlueMatrix’s leadership team is Bryan North-Clauss, appointed as its Chief Revenue Officer. Most recently, he held the position of Chief Revenue Officer at Truv, after leading AlphaSense's financial services sales division, where he contributed to growing its annual recurring revenue by 350% and productivity per salesperson by 400%. Earlier in his career, Bryan held senior roles in fixed income sales at Deutsche Bank, Morgan Stanley, Citi, and Lehman Brothers. His career began as a founding member of software firm JobDirect.com, acquired by Korn/Ferry.
Bryan North-Clauss stated: “This is a pivotal moment for me to join BlueMatrix and contribute to its ambitious expansion plans following January’s strategic investment by Thoma Bravo. Six months in, my focus remains on reinforcing our market dominance and share in our core verticals. For instance, 75% of all sell-side research is published using the BlueMatrix platform, highlighting our strong product-market fit and commitment to delivering world-class service. Moving forward, we aim to invest further in our clients' success to drive future growth.”
BlueMatrix’s continued growth strategy will focus on moving to new markets, including Europe, APAC region, and South America, to deliver technical expertise and client experience to a new audience of global clients. There will also be increased focus on enhancing the innovation that optimises workflows, scalability, and deep integration across its entire product suite to meet the evolving needs of its worldwide client base.
Patricia Horotan, Chief Executive Officer and President of BlueMatrix, said: “Our plans to expand our platform and portfolio of products for existing and new clients alike will not only reinforce our world-leading status, but bring the most advanced investment solutions to new generations of investors. Working with my leadership team, and in partnership with Thoma Bravo, we are excited to take BlueMatrix to new markets and new audiences.”
Founded in 1999, BlueMatrix employs 147 people, with 42% in the US and 39% in Romania. Expansion into new markets, including Europe, APAC region, and South America, is planned for the second half of this year, highlighting the company's international growth.
BlueMatrix offers fully integrated, cloud-based solutions for the entire investment research production workflow, including content creation, compliance approval, distribution, hosting, and analytics. This comprehensive suite positions BlueMatrix as the only global platform covering the complete investment research lifecycle.
About BlueMatrix
BlueMatrix, the world’s largest publisher of investment research, is a pioneering SaaS provider connecting content publishers and readers. Since 1999, BlueMatrix has developed advanced research-creation and distribution software for the financial services sell side, serving over 800 banks and institutions worldwide and supporting the production and publishing of 1.4 million items annually.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724453243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
